Your browser is no longer supported. Please, upgrade your browser.
VBLT Vascular Biogenics Ltd. monthly Stock Chart
VBLT [NASD]
Vascular Biogenics Ltd.
Index- P/E- EPS (ttm)-0.54 Insider Own26.73% Shs Outstand38.62M Perf Week10.70%
Market Cap53.01M Forward P/E- EPS next Y-0.62 Insider Trans0.00% Shs Float26.49M Perf Month11.60%
Income-19.50M PEG- EPS next Q-0.17 Inst Own22.50% Short Float0.14% Perf Quarter0.20%
Sales0.60M P/S88.36 EPS this Y12.60% Inst Trans- Short Ratio0.23 Perf Half Y3.99%
Book/sh1.00 P/B1.37 EPS next Y4.60% ROA-35.50% Target Price3.40 Perf Year-4.67%
Cash/sh0.95 P/C1.45 EPS next 5Y- ROE-45.20% 52W Range0.90 - 1.71 Perf YTD14.39%
Dividend- P/FCF- EPS past 5Y10.40% ROI-51.60% 52W High-19.73% Beta1.10
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin71.00% 52W Low52.52% ATR0.16
Employees38 Current Ratio4.30 Sales Q/Q0.00% Oper. Margin- RSI (14)55.44 Volatility8.37% 14.69%
OptionableYes Debt/Eq0.08 EPS Q/Q-35.90% Profit Margin- Rel Volume0.50 Prev Close1.35
ShortableYes LT Debt/Eq0.06 EarningsMar 19 BMO Payout- Avg Volume152.77K Price1.37
Recom1.80 SMA2015.95% SMA503.82% SMA2007.42% Volume75,723 Change1.68%
Jun-27-19Initiated Oppenheimer Outperform
Mar-09-18Downgrade Chardan Capital Markets Buy → Neutral $25 → $3
Mar-08-18Downgrade Piper Jaffray Overweight → Neutral
Mar-08-18Downgrade H.C. Wainwright Buy → Neutral $3
Nov-06-17Reiterated Chardan Capital Markets Buy $20 → $25
Jun-28-16Initiated H.C. Wainwright Buy $11
Nov-09-15Initiated Piper Jaffray Overweight
Oct-23-15Reiterated Chardan Capital Markets Buy $25 → $27.50
Sep-28-15Reiterated ROTH Capital Buy $13 → $22
Sep-22-15Initiated Chardan Capital Markets Buy $25
Sep-21-15Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-22-15Initiated ROTH Capital Buy $13
Apr-06-20 07:00AM  VBL Therapeutics Announces New Milestone Event in the VB-201 Collaboration for Veterinary Use GlobeNewswire +11.21%
Apr-02-20 09:00AM  Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier GlobeNewswire +6.90%
Mar-26-20 09:39PM  Edited Transcript of VBLT earnings conference call or presentation 19-Mar-20 12:30pm GMT Thomson Reuters StreetEvents +27.20%
07:57AM  VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study GlobeNewswire
Mar-21-20 09:02AM  Earnings Update: Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St.
Mar-19-20 10:33AM  Vascular Biogenics: Q4 Earnings Insights Benzinga +8.33%
08:15AM  Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:00AM  VBL Therapeutics Announces Year Ended December 31, 2019 Financial Results and Provides Corporate Update GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Mar-12-20 12:30PM  Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for Zacks -11.38%
Mar-02-20 08:00AM  VBL Therapeutics to Report Fourth Quarter 2019 Financial Results on March 19 GlobeNewswire
Feb-20-20 08:00AM  VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer GlobeNewswire
Feb-03-20 08:00AM  VBL Therapeutics to Present at the BIO CEO & Investor Conference GlobeNewswire
Jan-27-20 08:29AM  Will VBL Continue to Surge Higher? Zacks +5.41%
Jan-20-20 02:28PM  We're Hopeful That Vascular Biogenics (NASDAQ:VBLT) Will Use Its Cash Wisely Simply Wall St.
Jan-08-20 08:00AM  VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study GlobeNewswire
Nov-28-19 10:44PM  Should You Sell Vascular Biogenics Ltd. (VBLT)? Insider Monkey
Nov-21-19 08:00AM  VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting GlobeNewswire +6.31%
Nov-14-19 08:15AM  Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:00AM  VBL Therapeutics Announces Third Quarter 2019 Financial Results GlobeNewswire
Nov-07-19 10:30AM  Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Nov-06-19 08:00AM  VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma GlobeNewswire
Oct-31-19 08:00AM  VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14 GlobeNewswire
Oct-03-19 03:39PM  Easy Come, Easy Go: How Vascular Biogenics (NASDAQ:VBLT) Shareholders Got Unlucky And Saw 80% Of Their Cash Evaporate Simply Wall St.
Aug-13-19 08:25AM  Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:15AM  VBL Therapeutics Announces Second Quarter 2019 Financial Results GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Aug-06-19 10:30AM  Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Aug-05-19 08:00AM  VBL Therapeutics to Report Second Quarter 2019 Financial Results on August 13 GlobeNewswire -8.59%
Jul-31-19 02:43PM  Do Insiders Own Shares In Vascular Biogenics Ltd. (NASDAQ:VBLT)? Simply Wall St.
Jul-22-19 08:00AM  VBL Therapeutics Announces Modiin Production Facility Received a GMP Compliance Certificate Following EU QP Audit GlobeNewswire
Jun-04-19 07:00AM  VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today GlobeNewswire
Jun-03-19 08:00AM  VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer GlobeNewswire -8.03%
08:00AM  Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity GlobeNewswire
May-23-19 09:00AM  VBL Therapeutics Announces Presentations at the 2019 ASCO Annual Meeting and the BIO International Convention GlobeNewswire
May-16-19 07:52AM  Edited Transcript of VBLT earnings conference call or presentation 15-May-19 12:30pm GMT Thomson Reuters StreetEvents +7.44%
May-15-19 08:15AM  Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:09AM  Vascular Biogenics: 1Q Earnings Snapshot Associated Press
07:00AM  VBL Therapeutics Announces First Quarter 2019 Financial Results GlobeNewswire
May-14-19 05:16PM  Vascular Biogen Expected to Lose 12 Cents a Share TheStreet.com
May-08-19 10:30AM  Will Vascular Biogenics (VBLT) Report Negative Earnings Next Week? What You Should Know Zacks
May-06-19 08:00AM  VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15 GlobeNewswire
Apr-04-19 02:33PM  Those Who Purchased Vascular Biogenics (NASDAQ:VBLT) Shares Three Years Ago Have A 54% Loss To Show For It Simply Wall St.
Mar-29-19 07:19AM  Edited Transcript of VBLT earnings conference call or presentation 28-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
Mar-28-19 11:21AM  Vascular Biogenics (VBLT) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:54AM  The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO Benzinga
07:15AM  VBL Therapeutics Announces Year Ended December 31, 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-25-19 08:00AM  VBL Therapeutics to Present at Upcoming Conferences in April GlobeNewswire
Mar-21-19 10:30AM  Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for Zacks
Mar-19-19 07:00AM  VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microenvironment GlobeNewswire
Mar-14-19 10:30AM  Earnings Preview: Vascular Biogenics (VBLT) Q4 Earnings Expected to Decline Zacks
08:00AM  VBL Therapeutics to Report Fiscal Year 2018 Financial Results on March 28 GlobeNewswire
Mar-11-19 08:00AM  VBL Therapeutics to Present at the Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer on March 18 GlobeNewswire
Feb-26-19 08:00AM  VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA) GlobeNewswire +6.67%
Feb-20-19 08:00AM  VBL Therapeutics Awarded $2.9 Million Non-Dilutive Grant by the Israel Innovation Authority GlobeNewswire
Feb-19-19 08:00AM  VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26 GlobeNewswire
Dec-20-18 10:14AM  Read This Before Selling Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares Simply Wall St. -8.11%
Nov-21-18 09:28AM  Edited Transcript of VBLT earnings conference call or presentation 20-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
08:00AM  VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28 GlobeNewswire
Nov-20-18 08:15AM  Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:07AM  Vascular Biogenics: 3Q Earnings Snapshot Associated Press
07:00AM  VBL Therapeutics Announces Third Quarter 2018 Financial Results GlobeNewswire
Nov-16-18 07:00AM  VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting GlobeNewswire
Nov-13-18 07:00AM  VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20 GlobeNewswire
Oct-23-18 08:00AM  Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 until October 2033 GlobeNewswire
Oct-11-18 07:00AM  Data Presented at ECTRIMS 2018 Show Potential of MOSPD2 as a Novel Target for Treatment of CNS Inflammation, Such as Multiple Sclerosis GlobeNewswire -7.74%
Sep-17-18 08:00AM  VBL Therapeutics to Present at Upcoming Conferences in October GlobeNewswire
Aug-30-18 07:00AM  VBL Therapeutics Announces Publication of Positive New Data on its Lecinoxoid Drug Candidates for the Treatment of Renal Fibrosis GlobeNewswire
Aug-17-18 07:34AM  Edited Transcript of VBLT earnings conference call or presentation 16-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-16-18 09:37AM  The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga
08:15AM  Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:09AM  Vascular Biogenics: 2Q Earnings Snapshot Associated Press
07:00AM  VBL Therapeutics Announces Second Quarter 2018 Financial Results GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Aug-01-18 08:00AM  VBL Therapeutics to Report Second Quarter 2018 Financial Results on August 16 GlobeNewswire
Jul-10-18 08:00AM  Publication by VBL Therapeutics Highlights MOSPD2 as a Potential New Target for Breast Cancer Therapy GlobeNewswire
Jun-27-18 04:01PM  VBL Therapeutics Announces Closing of $15.5 Million Registered Direct Offering GlobeNewswire
Jun-26-18 08:57AM  VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -8.82%
Jun-20-18 07:05AM  Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-07-18 08:10AM  Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics ACCESSWIRE -13.33%
Jun-06-18 08:38AM  Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate Benzinga +39.53%
Jun-05-18 04:01PM  VBL Therapeutics Presents Positive Data on its MOSPD2 Platform Technology in Oncology and Inflammation at BIO 2018 GlobeNewswire
May-24-18 08:00AM  VBL Therapeutics to Present at Upcoming Conferences in June GlobeNewswire
May-18-18 08:31PM  Edited Transcript of VBLT earnings conference call or presentation 17-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-17-18 07:11AM  Vascular Biogenics: 1Q Earnings Snapshot Associated Press
07:00AM  VBL Therapeutics Announces First Quarter 2018 Financial Results GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
May-07-18 09:00AM  VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15 GlobeNewswire
May-01-18 08:00AM  VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17 GlobeNewswire
Apr-27-18 08:44AM  Vascular Biogenics (VBLT) Enters Oversold Territory Zacks
Apr-16-18 09:00AM  VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR GlobeNewswire -6.25%
Apr-12-18 08:52AM  Implied Volatility Surging for Vascular Biogenics (VBLT) Stock Options Zacks
Apr-10-18 08:00AM  VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16 GlobeNewswire +7.14%
Apr-09-18 08:00AM  VBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation Authority GlobeNewswire
Mar-15-18 06:31PM  Edited Transcript of VBLT earnings conference call or presentation 15-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
07:15AM  VBL Therapeutics Announces Year End 2017 Financial Results GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Mar-09-18 08:00AM  VBL Therapeutics to Report Fiscal 2017 Results on March 15 GlobeNewswire
Mar-08-18 09:00AM  Vascular Biogenics' stock plummets after brain cancer treatment trial fails MarketWatch
06:00AM  VBL Therapeutics Announces Top-Line Results from Pivotal Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma GlobeNewswire
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.